Tafinlar

Drug Overview
Product Profiles
Tafinlar : Non-small cell lung cancer (NSCLC)
Tafinlar : Melanoma

Figure 1: Tafinlar for non-small cell lung cancer – SWOT analysis
Figure 2: The authors drug assessment summary for Tafinlar in non-small cell lung cancer
Figure 3: The authors drug assessment summary for Tafinlar in non-small cell lung cancer
Figure 4: Tafinlar sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Tafinlar in melanoma – SWOT analysis
Figure 6: The authors drug assessment summary of Tafinlar for melanoma
Figure 7: The authors drug assessment summary of Tafinlar for melanoma
Figure 8: Tafinlar sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26

Table 1: Tafinlar drug profile
Table 2: Mekinist and Tafinlar pivotal trial data in non-small cell lung cancer
Table 3: Tafinlar sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Tafinlar patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 5: Tafinlar drug profile
Table 6: Tafinlar pivotal trial data in melanoma
Table 7: Tafinlar ongoing late-phase clinical trials in melanoma
Table 8: Tafinlar sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Tafinlar patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26